TNXP · Tonix Pharmaceuticals Holding Corp.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score Cluster buy
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-30 | SAENGER BRADLEY |
Chief Financial Officer |
Other↑
Filing footnotes — Common Stock, $0.001 par value (Direct)
Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan. |
Common Stock, $0.001 par value
|
1,453 |
| 2026-06-12 | Taylor Carolyn E. |
Director |
Buy↑
|
Common Stock, $0.001 par value
|
1,415 |
| 2026-06-09 | LEDERMAN SETH |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock, $0.001 par value (Direct)
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $11.735 to $11.883 per share. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. |
Common Stock, $0.001 par value
|
5,000 |
| 2026-06-08 | Stillwell Richard Newcomb |
Director |
Buy↑
Filing footnotes — Common Stock, $0.001 par value (Direct)
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $11.63 to $11.65 per share. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. |
Common Stock, $0.001 par value
|
5,000 |
| 2026-05-12 | BAGGER RICHARD H |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Stock Option
|
22,700 |
| 2026-05-12 | Bell Margaret Smith |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Stock Option
|
22,700 |
| 2026-05-12 | OLUKOTUN ADEOYE Y |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Stock Option
|
22,700 |
| 2026-05-12 | GRANGE DAVID L |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Stock Option
|
22,700 |
| 2026-05-12 | Treco James |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Stock Option
|
22,700 |
| 2026-05-12 | Hunter James Randolph Jr |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Stock Option
|
22,700 |
| 2026-05-12 | Stillwell Richard Newcomb |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Stock Option
|
22,700 |
| 2026-05-12 | Taylor Carolyn E. |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Stock Option
|
22,700 |
| 2026-03-31 | LEDERMAN SETH |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock, $0.001 par value (Indirect)
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.5699 to $12.625 per share. The Reporting Persons undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Reporting person may be deemed a control person of this entity. |
Common Stock, $0.001 par value
(I)
|
5,000 |
| 2026-03-18 | LEDERMAN SETH |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock, $0.001 par value (Indirect)
Reporting person may be deemed a control person of this entity. |
Common Stock, $0.001 par value
(I)
|
15,000 |
| 2026-02-24 | Fogarty Siobhan |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
39,012 |
| 2026-02-24 | MORRIS JESSICA EDGAR |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
39,012 |
| 2026-02-24 | SULLIVAN GREGORY M |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
39,012 |
| 2026-02-24 | SULLIVAN GREGORY M |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
39,011 |
| 2026-02-24 | LEDERMAN SETH |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
134,503 |
| 2026-02-24 | LEDERMAN SETH |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
134,504 |
| 2026-02-24 | Fogarty Siobhan |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
39,011 |
| 2026-02-24 | SAENGER BRADLEY |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
39,012 |
| 2026-02-24 | SAENGER BRADLEY |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
39,011 |
| 2026-02-24 | MORRIS JESSICA EDGAR |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. |
Stock Option
|
39,011 |
| 2025-08-21 | Taylor Carolyn E. |
Director |
Buy↑
Filing footnotes — Common Stock, par value $0.001 (Direct)
Represents the weighted average purchase price. Actual purchase prices ranged from $35.98 to $36.05. |
Common Stock, par value $0.001
|
418 |
| 2025-08-20 | Treco James |
Director |
Buy↑
|
Common Stock, par value $0.001
|
250 |
| 2025-06-12 | Hunter James Randolph Jr |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests on the date of the Company's 2026 annual meeting of stockholders. |
Stock Option
|
7,740 |
| 2025-05-15 | LEDERMAN SETH |
Director, Chief Executive Officer |
Buy↑
|
Common Stock, $0.001 par value
|
4,000 |
| 2025-05-13 | Taylor Carolyn E. |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. |
Stock Option
|
10,000 |
| 2025-05-13 | BAGGER RICHARD H |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. |
Stock Option
|
10,000 |
| 2025-05-13 | GRANGE DAVID L |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. |
Stock Option
|
10,000 |
| 2025-05-13 | Treco James |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. |
Stock Option
|
10,000 |
| 2025-05-13 | Bell Margaret Smith |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. |
Stock Option
|
10,000 |
| 2025-05-13 | Stillwell Richard Newcomb |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. |
Stock Option
|
10,000 |
| 2025-05-13 | OLUKOTUN ADEOYE Y |
Director |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. |
Stock Option
|
10,000 |
| 2025-02-25 | LEDERMAN SETH |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
123,958 |
| 2025-02-25 | Fogarty Siobhan |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
13,500 |
| 2025-02-25 | MORRIS JESSICA EDGAR |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
29,291 |
| 2025-02-25 | MORRIS JESSICA EDGAR |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
29,291 |
| 2025-02-25 | LEDERMAN SETH |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
123,958 |
| 2025-02-25 | SAENGER BRADLEY |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
25,792 |
| 2025-02-25 | Fogarty Siobhan |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
13,500 |
| 2025-02-25 | SAENGER BRADLEY |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
25,792 |
| 2025-02-25 | SULLIVAN GREGORY M |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
29,017 |
| 2025-02-25 | SULLIVAN GREGORY M |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Direct)
The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. |
Stock Option
|
29,017 |
| 2025-02-05 | Bell Margaret Smith |
Director |
Other↓
Filing footnotes — Common Stock, par value $0.001 (Direct)
Involuntary sale of fractional shares following a reverse stock split of the Issuer's common stock. |
Common Stock, par value $0.001
|
1 |
| 2025-02-05 | SAENGER BRADLEY |
Chief Financial Officer |
Other↓
Filing footnotes — Common Stock, par value $0.001 (Direct)
Shares were surrendered without considerations following a reverse stock split of the Issuer's common stock. |
Common Stock, par value $0.001
|
0 |
| 2025-02-05 | SULLIVAN GREGORY M |
Chief Medical Officer |
Other↓
Filing footnotes — Common Stock, par value $0.001 (Direct)
Involuntary sale of fractional shares following a reverse stock split of the Issuer's common stock |
Common Stock, par value $0.001
|
0 |
| 2025-02-05 | BAGGER RICHARD H |
Director |
Other↓
Filing footnotes — Common Stock, par value $0.001 (Direct)
Involuntary sale of fractional shares following a reverse stock split of the Issuer's comment stock. |
Common Stock, par value $0.001
|
0 |
| 2025-02-05 | LEDERMAN SETH |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Common Stock, $0.001 par value (Indirect)
Involuntary sale of fractional share following a reverse stock split of the Issuer's common stock. |
Common Stock, $0.001 par value
(I)
|
1 |